Biotech · Private company · Cambridge, MA, US
Blueprint Medicines Corp
SEC CIK 0001597264
Track this companyFree. Adds Blueprint Medicines Corp to your Dealase workspace and tells you when its record changes.
Clinical trials257 recruiting or active
Pipeline programs34From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline34
- avapritinibPhase 3 · GISTClinicalTrials.gov · fetched Nov 12, 2026
- ElenestinibPhase 3 · Indolent Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- regorafenibPhase 3 · GISTClinicalTrials.gov · fetched Nov 12, 2026
- avapritinibPhase 2 · Solid Tumor, Unspecified, ChildClinicalTrials.gov · fetched Nov 12, 2026
- AvapritinibPhase 2 · Advanced Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- AvapritinibPhase 2 · Indolent Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- BLU-808Phase 2 · Chronic Inducible UrticariaClinicalTrials.gov · fetched Nov 12, 2026
- BLU-924Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- AvapritinibPhase 1 · Aggressive Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- AvapritinibPhase 1 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AvapritinibPhase 1 · Gastrointestinal Stromal Tumors (GIST)ClinicalTrials.gov · fetched Nov 12, 2026
- AzacitidinePhase 1 · Advanced Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- BLU-222Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- BLU-263Phase 1 · Advanced Systemic MastocytosisClinicalTrials.gov · fetched Nov 12, 2026
- BLU-451Phase 1 · Lung Neoplasm MalignantClinicalTrials.gov · fetched Nov 12, 2026
- BLU-701Phase 1 · Lung NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- BLU-808Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- BLU-945Phase 1 · Lung NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- carboplatinPhase 1 · Lung NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Lung Neoplasm MalignantClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ElenestinibPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- Fisogatinib (BLU-554)Phase 1 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Levonorgestrel/Ethinyl EstradiolPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- midazolamPhase 1 · Gastrointestinal Stromal TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- osimertinibPhase 1 · Lung NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- osimertinibPhase 1 · Lung NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- pemetrexedPhase 1 · Lung NeoplasmClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 1 · Lung Neoplasm MalignantClinicalTrials.gov · fetched Nov 12, 2026
- RibociclibPhase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ScreeningClonal Mast Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ScreeningSystemic Mast Cell ActivationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsPHASE1_PHASE2 · RECRUITING · started Jun 4, 2026ClinicalTrials.gov NCT07629960 · fetched Nov 12, 2026
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)RECRUITING · started Apr 15, 2026ClinicalTrials.gov NCT07264959 · fetched Nov 12, 2026
- A Study of Elenestinib in Healthy Adult Female ParticipantsPHASE1 · COMPLETED · started Feb 5, 2026ClinicalTrials.gov NCT07388511 · fetched Nov 12, 2026
- Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRECRUITING · started Oct 17, 2025ClinicalTrials.gov NCT07143669 · fetched Nov 12, 2026
- Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)PHASE2 · ACTIVE_NOT_RECRUITING · started May 28, 2025ClinicalTrials.gov NCT06931405 · fetched Nov 12, 2026
- Study of BLU-808 in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Aug 7, 2024ClinicalTrials.gov NCT06948032 · fetched Nov 12, 2026
- Avapritinib With Decitabine in Patients With SM-AHNPHASE1 · RECRUITING · started Mar 13, 2024ClinicalTrials.gov NCT06327685 · fetched Nov 12, 2026
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesPHASE1 · TERMINATED · started Sep 25, 2023ClinicalTrials.gov NCT05609942 · fetched Nov 12, 2026
- A Drug-drug Interaction Study of Avapritinib and MidazolamPHASE1 · COMPLETED · started Aug 24, 2022ClinicalTrials.gov NCT04908176 · fetched Nov 12, 2026
- (VELA) Study of BLU-222 in Advanced Solid TumorsPHASE1 · TERMINATED · started Apr 7, 2022ClinicalTrials.gov NCT05252416 · fetched Nov 12, 2026
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsPHASE1 · TERMINATED · started Mar 4, 2022ClinicalTrials.gov NCT05241873 · fetched Nov 12, 2026
- A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingPHASE1_PHASE2 · COMPLETED · started Feb 24, 2022ClinicalTrials.gov NCT04773782 · fetched Nov 12, 2026
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCPHASE1 · TERMINATED · started Jan 13, 2022ClinicalTrials.gov NCT05153408 · fetched Nov 12, 2026
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisPHASE2_PHASE3 · RECRUITING · started Nov 30, 2021ClinicalTrials.gov NCT04910685 · fetched Nov 12, 2026
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCPHASE1 · TERMINATED · started Jun 29, 2021ClinicalTrials.gov NCT04862780 · fetched Nov 12, 2026
- (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell ActivationCOMPLETED · started Jun 29, 2021ClinicalTrials.gov NCT04811365 · fetched Nov 12, 2026
- Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMCOMPLETED · started Dec 2, 2020ClinicalTrials.gov NCT04695431 · fetched Nov 12, 2026
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCUNKNOWN · started Dec 1, 2020ClinicalTrials.gov NCT04697446 · fetched Nov 12, 2026
- Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World SettingUNKNOWN · started Aug 15, 2020ClinicalTrials.gov NCT05826756 · fetched Nov 12, 2026
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 16, 2019ClinicalTrials.gov NCT03731260 · fetched Nov 12, 2026
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisPHASE2 · COMPLETED · started Nov 21, 2018ClinicalTrials.gov NCT03580655 · fetched Nov 12, 2026
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTPHASE3 · COMPLETED · started Mar 26, 2018ClinicalTrials.gov NCT03465722 · fetched Nov 12, 2026
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesPHASE1 · COMPLETED · started Mar 10, 2016ClinicalTrials.gov NCT02561988 · fetched Nov 12, 2026
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsPHASE1 · COMPLETED · started Aug 1, 2015ClinicalTrials.gov NCT02508532 · fetched Nov 12, 2026
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaPHASE1 · COMPLETED · started Jul 31, 2015ClinicalTrials.gov NCT02508467 · fetched Nov 12, 2026
SEC filings9
- 8-K · 8-KSEC EDGAR · filed Jul 18, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 20, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 2, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 1, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 1, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 18, 2024 · fetched Nov 12, 2026